Key takeaway: Viyash Scientific Limited's investor presentation for Q1 FY 2026-27 reported a revenue of ₹9,464 million, reflecting a 19.5% year-over-year increase. EBITDA reached ₹2,047 million, marking a 59.2% increase from the previous year, with an EBITDA margin of 21.6%, up 530 basis points. Management highlighted the successful integration efforts and the acquisition of Bio For Life in Italy, which aligns with their strategic focus on the companion animal segment. The presentation detailed a disciplined approach to operational efficiency and strategic investments aimed at sustainable growth. The company also reported a net debt of ₹1,661 million, with a net debt to EBITDA ratio of 0.1x, down from 0.2x in Q4 FY26. Overall, the document emphasized strong financial performance and strategic initiatives to enhance market presence.

Key takeaway: Viyash Scientific Limited's earnings conference call for Q4 FY26 highlighted a transformative year for the company, with management reporting a record EBITDA surpassing INR 200 crores and a significant increase in profit after tax (PAT) by 1,324%. The company achieved a total revenue of INR 920 crores for the quarter, reflecting a year-on-year growth of 19.1%. Management emphasized the successful integration of business operations and the strong performance of both animal and human health segments. They noted a focus on expanding product pipelines and operational efficiencies, with plans for selective inorganic growth opportunities. The call also addressed the company's strong balance sheet and improved credit ratings, alongside a commitment to maintaining margins while investing in R&D and capacity expansion. Management expressed confidence in achieving sustainable growth and enhancing synergies from the merger.

Key takeaway: Viyash Scientific Limited reported that fiscal year 2026 was transformative, highlighted by the successful integration of facilities and operations. Management noted that Q4 was the strongest quarter in the company's history, with merger synergies positively impacting financial performance. The presentation detailed a 19.1% year-over-year increase in Q4 revenues to ₹9,200 million and a 63.8% increase in EBITDA to ₹2,001 million, resulting in an EBITDA margin of 21.7%. For the full fiscal year, revenues reached ₹34,203 million, up 13.8% year-over-year, with EBITDA increasing by 59.6% to ₹7,025 million. Management emphasized disciplined asset utilization and cost controls amid geopolitical challenges and expressed excitement about the product pipeline and growth roadmap. The merger has been approved by regulatory authorities, and management is focused on realizing synergies over the next 12 months.

Key takeaway: Viyash Scientific Limited held its Q3 FY'26 earnings conference call on February 6, 2026, where management discussed the financial performance of the merged entity. Dr. Hari Babu, Managing Director, reported that revenue from operations for the quarter was INR 858 crores, reflecting an 11% year-on-year growth, while adjusted EBITDA surged 64% to INR 185 crores, with an EBITDA margin of 21%. The company highlighted a significant reduction in net debt-to-EBITDA to less than 4x. Management noted that the performance was broad-based across segments and geographies, with a focus on companion animals and CDMO opportunities. They also addressed one-time exceptional items related to merger execution totaling approximately INR 49 crores. CFO Ramakant Singani provided further insights into the financials, emphasizing strong operational performance and a solid financial position. The call concluded with management expressing confidence in sustaining growth and profitability moving forward.

Key takeaway: Viyash Scientific Limited, in its investor presentation dated February 6, 2026, reported its financial results for Q3 FY 2025-26, marking the first results of the merged entity. Management highlighted strong growth in revenue, margins, and profitability, attributing this to new product introductions, cost improvements, and synergies from the merger. The company reported revenues of ₹8,584 million, an 11% year-over-year increase, and an EBITDA of ₹1,854 million, reflecting a 64% increase year-over-year. The presentation detailed broad-based revenue growth across various segments, with notable performance in formulations and APIs. Management emphasized the strong balance sheet and market position, expressing optimism about capturing market opportunities in the coming years. The merger is reported to be generating benefits across R&D, manufacturing, and sales functions, with a focus on synergy realization over the next 12 months.